Literature DB >> 11948541

Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.

Li Shi1, Michael J Caulfield, Rey T Chern, Roger A Wilson, Gautam Sanyal, David B Volkin.   

Abstract

A single-shot Hepatitis B vaccine formulation using poly(d,l)-lactide-co-glycolide acid (PLGA) microspheres as a delivery system was examined using a variety of biophysical and biochemical techniques as well as immunological evaluation in C3H mice. PLGA microsphere encapsulation of the Hepatitis B surface antigen (HBsAg), a lipoprotein particle, resulted in good recoveries of protein mass, protein particle conformational integrity, and in vitro antigenicity. Some partial delipidation of the HBsAg, however, was observed. The loading and encapsulation efficiency of HBsAg into the PLGA microspheres were measured along with the morphology and size distribution of the vaccine-loaded PLGA microspheres. The in vitro release kinetics of HBsAg from the PLGA microspheres was evaluated and found to be affected by experimental conditions such as stirring rate. HBsAg showed enhanced storage stability at 37 degrees C in the slightly acidic pH range reported to be found inside PLGA microspheres; thus, the antigen is relatively stable under conditions of temperature and pH that may mimic in vivo conditions. The immunogenicity of the microsphere formulations of HBsAg was compared with conventional aluminum adjuvant formulated HBsAg vaccine in C3H mice. Comparisons were made between aluminum formulations (one and two injections), PLGA microsphere formulations (single injection), and a mixture of aluminum and PLGA microsphere formulations (single injection). The nine-month serum antibody titers indicate that a single injection of a mixture of aluminum and PLGA-formulated HBsAg results in equal or better immune responses than two injections of aluminum-formulated HBsAg vaccine. Based on these in vitro and in vivo studies, it is concluded that HBsAg can be successfully encapsulated and recovered from the PLGA microspheres and a mixture of aluminum-adjuvanted and PLGA-formulated HBsAg can auto-boost an immune response in manner comparable to multiple injections of an aluminum-formulated vaccine. Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:1019-1035, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948541     DOI: 10.1002/jps.10042

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

1.  Recombinant human hepatitis B vaccine initiating alopecia areata: testing the hypothesis using the C3H/HeJ mouse model.

Authors:  John P Sundberg; Kathleen A Silva; Weidong Zhang; Beth A Sundberg; Kathryn Edwards; Lloyd E King; Robert L Davis; Steven Black
Journal:  Vet Dermatol       Date:  2009-01-17       Impact factor: 1.589

2.  Sequential release of nanoparticle payloads from ultrasonically burstable capsules.

Authors:  Stephen Kennedy; Jennifer Hu; Cathal Kearney; Hadas Skaat; Luo Gu; Marco Gentili; Herman Vandenburgh; David Mooney
Journal:  Biomaterials       Date:  2015-10-22       Impact factor: 12.479

3.  Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Authors:  Claudia Carvalho-Queiroz; Rosemary Cook; Ching C Wang; Rodrigo Correa-Oliveira; Nicola A Bailey; Nejat K Egilmez; Edith Mathiowitz; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

4.  Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery.

Authors:  Thejani E Rajapaksa; Mary Stover-Hamer; Xiomara Fernandez; Holly A Eckelhoefer; David D Lo
Journal:  J Control Release       Date:  2009-11-05       Impact factor: 9.776

Review 5.  Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.

Authors:  Akhilesh Kumar Shakya; Kutty Selva Nandakumar
Journal:  J R Soc Interface       Date:  2013-02       Impact factor: 4.118

6.  Sustained levels of FGF2 maintain undifferentiated stem cell cultures with biweekly feeding.

Authors:  Steven Lotz; Susan Goderie; Nicolas Tokas; Sarah E Hirsch; Faizzan Ahmad; Barbara Corneo; Sheila Le; Akhilesh Banerjee; Ravi S Kane; Jeffrey H Stern; Sally Temple; Christopher A Fasano
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

7.  Protective effect of recombinant staphylococcal enterotoxin A entrapped in polylactic-co-glycolic acid microspheres against Staphylococcus aureus infection.

Authors:  Liben Chen; Shuang Li; Zhengfang Wang; Ruilong Chang; Jingliang Su; Bo Han
Journal:  Vet Res       Date:  2012-03-19       Impact factor: 3.683

8.  Protective Potential of Antioxidant Enzymes as Vaccines for Schistosomiasis in a Non-Human Primate Model.

Authors:  Claudia Carvalho-Queiroz; Ruth Nyakundi; Paul Ogongo; Hitler Rikoi; Nejat K Egilmez; Idle O Farah; Thomas M Kariuki; Philip T LoVerde
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

9.  Fabrication and characterization of DDAB/PLA-alginate composite microcapsules as single-shot vaccine.

Authors:  Meiyang Yang; Tingyuan Yang; Jilei Jia; Ting Lu; Hailin Wang; Xueying Yan; Lianyan Wang; Lian Yu; Yue Zhao
Journal:  RSC Adv       Date:  2018-04-11       Impact factor: 4.036

10.  Impact evaluation of the routine hepatitis B vaccination program of infants in China.

Authors:  Mei Sun; Chengyue Li; Pingping Li; Jun Lu; Ying Wang; Fengshui Chang; Xiaohong Li; Mo Hao
Journal:  J Public Health (Oxf)       Date:  2019-03-01       Impact factor: 2.341

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.